Industries > Pharma > Global Precision Medicine Market Forecast 2018-2028

Global Precision Medicine Market Forecast 2018-2028

Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular Diseases, Central Nervous System, Infectious Diseases

PUBLISHED: 26 March 2018
PAGES: 233
PRODUCT CODE: PHA0295

Clear
WOOCS 2.2.1

The global precision medicine market is expected to grow at an estimated CAGR of 12.08% from 2018 to 2028. The diagnostic tool companies segment is dominating the global market and accounted for $15,974.4 million in 2017 due to the increasing demand for diagnostic and genetic tests.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 233-page report you will receive 116 tables and 56 figures– all unavailable elsewhere.

The 233-page report provides clear detailed insight into the global precision medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Precision Medicine Market forecasts from 2018-2028

• Along with revenue prediction for the overall market for the global precision medicine market, our investigation shows forecasts to 2028 for the market segmented by technology:
• Companion Diagnostics
• Biomarker-based Test
• Targeted Therapeutics
• Pharmacogenomics
• Molecular Diagnostics

The forecast for each market segment is further broken down by ecosystem player and therapeutic application

For each segment, the report discusses key trends, developments and participants.

• This report breaks down the precision medicine market forecast to 2028 by ecosystem players:
• Pharmaceuticals & Biotechnology Companies
• Diagnostic Companies
• Healthcare IT/Big Data Companies
• Clinical Laboratories

The forecast for each market segment is further broken down by technology, therapeutic application and geography.

For each segment, the report discusses key trends, developments and participants.

• This report also breaks down the precision medicine market forecast to 2028 by therapeutic application:
• Cancer
• Cardiovascular Diseases
• Central Nervous System
• Infectious Diseases

The forecast for each market segment is further broken down by ecosystem player, technology and geography.

For each segment, the report discusses key trends, developments and participants.

• This study provides precision medicine market forecasts to 2028 for these regional markets:
• The Americas
• Europe
• Asia-Pacific
• RoW

The forecast for each regional market is further broken down by ecosystem player and therapeutic application

For each regional market, the report discusses key trends, developments and participants.

• This report profiles selected leading companies that are the main players in the global precision medicine market:
• Abbott Laboratories
• GE Healthcare
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Pfizer
• Laboratories Corporation of America Holdings
• Danaher Corporation

Global Precision Medicine Market Forecast 2018-2028

• Our study discusses the drivers, restraints as well as the opportunities in the global precision medicine market.

• This study also analyzed the global precision medicine market with Porter’s Five Forces Analysis as well as Value Chain Analysis

• This report discusses selected market developments in the precision medicine market: partnership, collaboration, join venture, acquisitions, product launch, product development, expansions, patents, approvals.

Visiongain’s study is intended for anyone requiring commercial analyses for the global precision medicine market. You find data, trends and predictions.

Buy our report today Global Precision Medicine Market Forecast 2018-2028: Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular Diseases, Central Nervous System, Infectious Diseases.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Precision Medicine Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Precision Medicine Market Forecast 2018-2028


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category